AI MARKET SCANNING

Alnylam Pharmaceuticals, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -2.40%
MAX GAP RECORD -21.49%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ALNY
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Oct 29, 2026 Earnings Release 2026-10-29 (BEFORE OPEN (08:00))
-20.14%
Jul 30, 2026 Earnings Release 2026-07-30 (BEFORE OPEN)
-21.49%
Apr 30, 2026 Earnings Release 2026-04-30 (BEFORE OPEN)
+2.09%
Feb 12, 2026 Earnings Release 2026-02-12 (BEFORE OPEN)
-0.30%
Oct 30, 2025 Earnings Release 2025-10-30 (BEFORE OPEN)
-6.56%
Jul 31, 2025 Earnings Release 2025-07-31 (BEFORE OPEN)
+3.00%
Apr 30, 2025 Earnings Release 2025-04-30 (BEFORE OPEN)
-2.42%
Feb 13, 2025 Earnings Release 2025-02-13 (BEFORE OPEN)
+1.43%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.8%
Bullish Gaps (7)
Bearish Gaps (7)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ALNY

EXECUTIONS2 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-29 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 498m +1.24%
••••-••-•• 🔒 LOCKED ••• x• $•••.•• → $•••.•• ••m +••.••%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria;…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗